<DOC>
	<DOCNO>NCT01130688</DOCNO>
	<brief_summary>The leukemic stem cell ( LSCs ) cell self- renew give rise leukemia . Eradication LSC require cure . In chronic myelogenous leukemia ( CML ) LSCs eradicate imatinib ( Gleevec ) alone . Recent discovery Dr. Shaoguang Li University Massachusetts indicate LSCs target new drug zileuton ( Chen et al . Nature Genetics 2009 ; 41:783-792 ) . Zileuton ( approve asthma ) test combination Gleevec . This combination use previously treat leukemia . This Phase I study . The goal research evaluate safety standard anti-cancer drug imatinib experimental drug zileuton .</brief_summary>
	<brief_title>Safety Zileuton ( Zyflo ) Combination With Imatinib Mesylate ( Gleevec ) CML .</brief_title>
	<detailed_description>More twenty two thousand people live chronic myelogenous leukemia United States five thousand people expect diagnosed year . The majority patient disease diagnose call chronic phase . The standard treatment phase disease therapy medication call imatinib . This treatment diminish amount disease low level sensitive specialize technique measure ; , however , provide cure . Dr. Shaoguang Li colleague University Massachusetts publish unique discovery arachidonate 5-lipoxygenase ( 5-LO ) gene ( Alox5 ) critical regulator LSCs BCR-ABL-induced CML ( Chen Y et al . Loss Alox5 gene impairs leukemia stem cell prevent chronic myeloid leukemia . Nature Genetics 41:783-792 , 2009 ) . In absence Alox5 , BCR-ABL fail induce CML preclinical study . While deficiency Alox5 effect normal hematopoiesis , impairment LSCs function differentiation cell division CML LSCs observe . This defect lead depletion LSCs failure CML development . Treatment 5-LO inhibitor ( zileuton ) also impaired function LSCs prolong survival . These result demonstrate specific target gene find cancer stem cell inhibition completely inhibit function stem cell . These finding provide excite opportunity develop first anti-cancer stem cell therapy treat CML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<criteria>Patients CML chronic phase ( patient already imatinib ) Presence Philadelphia chromosome bcrabl rearrangement Age ≥ 18 year ECOG performance status ≤ 2 Written inform consent Hepatic dysfunction ( serum bilirubin ≥ 2 x ULN , and/or ALT ≥ 3 x ULN , and/or AST ≥ 3 x ULN ) Renal dysfunction ( creatinine ≥ 200 μmol/l 2.3 mg/dl ) Severe cardiac dysfunction ( NYHA classification IIIIV ) Severe pulmonary neurologic disease Pregnant lactating female Patients history active malignancy past 5 year exception nonmetastatic skin cancer ( e.g . treat squamous basal cell carcinoma ) stage 0 cervical carcinoma Patients know HIVpositive Patients active , uncontrolled infection Male female patient reproductive potential practicing effective mean contraception Patients know allergic reaction intolerance either imatinib zileuton Patients require anticoagulation therapy coumadin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Zileuton</keyword>
	<keyword>myeloproliferative neoplasm</keyword>
</DOC>